WooGene B&G Past Earnings Performance
Past criteria checks 0/6
WooGene B&G has been growing earnings at an average annual rate of 34.8%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 12.3% per year.
Key information
34.8%
Earnings growth rate
46.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 12.3% |
| Return on equity | -1.6% |
| Net Margin | -2.0% |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How WooGene B&G makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 57,919 | -1,184 | 10,821 | 907 |
| 30 Sep 23 | 49,120 | -9 | 8,821 | 683 |
| 30 Jun 23 | 47,802 | 894 | 8,309 | 474 |
| 31 Mar 23 | 44,878 | 179 | 7,595 | 336 |
| 31 Dec 22 | 43,703 | 850 | 6,661 | 270 |
| 30 Sep 22 | 47,578 | -1,351 | 6,756 | 289 |
| 30 Jun 22 | 45,964 | -1,446 | 6,359 | 284 |
| 31 Mar 22 | 41,535 | -828 | 6,319 | 327 |
| 31 Dec 21 | 39,347 | -2,258 | 6,427 | 305 |
| 30 Sep 21 | 34,790 | -3,550 | 5,732 | 248 |
| 30 Jun 21 | 34,516 | -2,082 | 5,901 | 201 |
| 31 Mar 21 | 38,287 | -4,243 | 6,154 | 148 |
| 31 Dec 20 | 39,524 | -3,030 | 6,246 | 105 |
| 30 Sep 20 | 42,980 | -2,224 | 6,670 | 98 |
| 30 Jun 20 | 40,141 | -2,925 | 6,302 | 42 |
| 31 Mar 20 | 36,154 | -522 | 5,870 | 15 |
| 31 Dec 19 | 29,656 | -333 | 5,560 | 59 |
| 30 Sep 19 | 27,211 | 349 | 5,557 | 110 |
| 30 Jun 19 | 27,524 | -1,602 | 5,599 | 104 |
| 31 Mar 19 | 28,208 | -4,843 | 5,616 | 116 |
| 31 Dec 18 | 28,131 | -6,632 | 5,766 | 106 |
| 31 Dec 17 | 22,934 | -4,190 | 6,866 | 513 |
| 30 Sep 13 | 19,509 | 368 | 5,607 | 0 |
| 30 Jun 13 | 20,942 | 944 | 5,656 | 0 |
Quality Earnings: A018620 is currently unprofitable.
Growing Profit Margin: A018620 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A018620 is unprofitable, but has reduced losses over the past 5 years at a rate of 34.8% per year.
Accelerating Growth: Unable to compare A018620's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A018620 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (34.6%).
Return on Equity
High ROE: A018620 has a negative Return on Equity (-1.64%), as it is currently unprofitable.